|Positive WB detected in||HeLa cells, SGC-7901 cells, MCF-7 cells|
|Positive IP detected in||SGC-7901 cells|
|Positive IHC detected in||human breast cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||human breast cancer tissue|
|Positive FC detected in||MCF-7 cells|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:300-1:1200|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
18299-1-AP targets HER2/ErbB2 in WB, IP, IHC, IF, FC,ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Full Name||v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)|
|Calculated molecular weight||138 kDa|
|Observed molecular weight||185 kDa|
|GenBank accession number||BC167147|
|Gene ID (NCBI)||2064|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase- mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.
|Product Specific Protocols|
|WB protocol for HER2/ErbB2 antibody 18299-1-AP||Download protocol|
|IHC protocol for HER2/ErbB2 antibody 18299-1-AP||Download protocol|
|IF protocol for HER2/ErbB2 antibody 18299-1-AP||Download protocol|
|IP protocol for HER2/ErbB2 antibody 18299-1-AP||Download protocol|
|FC protocol for HER2/ErbB2 antibody 18299-1-AP||Download protocol|
|Click here to view our Standard Protocols|
SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis.
ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control.
J Immunol Res
Efficient Acquisition of Fully Human Antibody Genes against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes.
Pathol Res Pract
Pathol Res Pract
Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.